The FDA grants 501(k) clearance to BioCardia’s (OTCQB:BCDA) Morph DNA deflectable guide catheter used to guide the Helix Biotherapeutic Delivery System during CardiAMP cell therapy delivery in the heart. The company says Morph DNA enables navigation within the heart’s chambers without building up torque.
Shares down 5% premarket on average volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.